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Formation of reactive oxygen metabolites in glomeruli is
suppressed by inhibition of cAMP phosphodiesterase
isozyme type IV
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Formation of reactive oxygen metabolites in glomeruli is suppressed by
inhibition of cAMP phosphodiesterase isozyme type IV. Several indepen-
dent studies indicate that synthetic inhibitors of cyclic-3',5'-nucleotide
phosphodiesterase (PDE) isozymes, especially inhibitors of PDE-IV,
are potent agents which suppress generation of reactive oxygen metab-
olites (ROM) by NADPH oxidase in leukocytes. Recent studies also
show that NADPH oxidase is present in all cell types populating
glomeruli. In view of this, we investigated PDE isozymes and their
relation to ROM in isolated rat glomeruli. Glomeruli have the capacity
to hydrolyze cAMP by isozymes PDE-II, PDE-III and PDE-IV,
whereas cGMP is hydrolyzed by PDE-I and PDE-V. Inhibitor of
PDE-IV rolipram inhibited significantly (cca 40 to 50%) ROM genera-
tion in response to stimulation by phorbol myristate acetate (PMA).
Inhibitor of PDE-III cilostamide had only minor suppressive effects and
inhibitors of other PDE isozymes did not influence ROM generation.
Rolipram (3 /Las) suppressed ROM generation without detectable in-
crease in cAMP content. Incubation of glomeruli with forskolin, which
increased cAMP content in glomeruli tenfold, inhibited ROM genera-
tion to a similar degree as rolipram. The suppression of ROM genera-
tion by rolipram was prevented by Rp-cAMPS, a specific inhibitor of
protein kinase A (PKA) activity. Further, incubation of glomeruli with
rolipram elicited marked in situ activation of PKA (+ 100%), as docu-
mented by increase in the (—cAMP/+cAMP) PKA activity ratio. We
suggest that selective inhibitor of PDE-IV rolipram acted via the
cAMP-signaling pathway and suppressed ROM generation possibly via
phosphorylating ras-type GTP-binding protein component of NADPH
oxidase and thereby blocking assembly of functional NADPH oxidase
complex. Results also suggest that ROM burst in glomeruli is modulated
by a distinct CAMP-signaling pathway which is controlled by PDE-IV.
We surmise that inhibitors of PDE-IV might be effective agents for
suppression of ROM generation in glomeruli in vivo and attenuation of
glomerular injury.
generated within endogenous renal cells residing in glomeruli
[3] could be a major and perhaps a determining noxious factor
in the pathogenesis of various inflammatory or non-inflamma-
tory glomerular diseases [1, 2, 4].
In view of cytotoxic effects of ROM generated in glomeruli
[31, investigations of novel pharmacologic interventions which
are aimed to decrease the content of ROM in glomeruli, either
by blocking ROM generation and/or by increasing the rate of
ROM inactivation in the glomerular cells, are highly desirable.
One frequently employed experimental approach to lower ROM
content in the kidney tissue relies on administration of enzy-
matic or nonenzymatic ROM scavengers or antioxidants some-
times applied in very high doses [1, 2, 4]. Another approach to
prevent or diminish cell damage by ROM involves maneuver(s)
aimed to decrease ROM generation in situ. Some studies of
professional inflammatory-infiltrating cells, that is, neutrophils
[5, 6], eosinophils [71-or macrophages [8] indicate that increased
levels of intracellular cAMP can suppress the burst of ROM
generation [5—10] via inhibition of NADPH oxidase, a major
source of ROM in these cells [11, 12]. In this context, of
particular interest and potential importance are recent observa-
tions which show that newly designed specific synthetic "2nd
generation" inhibitors [13, 14] of some isozymes of cyclic-
3' ,5'-nucleotides phosphodiesterases' namely inhibitors
of PDE-IV, in a very low concentration can block the ROM
Numerous experimental findings support the thesis that re-
active oxygen metabolites (ROM) play an important role in the
mechanism(s) of cell injury in a variety of pathophysiological
situations [1] in various tissues, including kidney [1, 2]. With
respects of glomerulopathies, ROM generated by infiltrating
leukocytes, namely neutrophils and macrophages [1], or ROM
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'PDE denotes cyclic-3' ,5'-nucleotide phosphodiesterase in general.
cAMP-PDE denotes PDE activity using cAMP as substrate,
cGMP-PDE denotes PDE activity using cGMP as substrate.
In this report, the PDE isozymes are classified as proprosed by Dr.
J.A. Beavo [13, 14]. According to this nomenclature, PDE-I is the
family (also called "type") of PDE isozymes dependent on ionized
calcium (Ca2) and calinodulin (CaM); PDE-II is the family of isozymes
cAMP-PDE activity of which is stimulated by low (M range) concen-
tration of cGMP; the PDE-III are isozymes with low Km for cAMP and
are sensitive to inhibition by cilostamide, "cardiotonic inhibitors" and
cGMP but are not inhibited by rolipram or Ro-20-l724; PDE-IV are
isozymes with very high affinity and selectivity for cAMP, are insensi-
tive to compounds that inhibit PDE-III and are selectively inhibited by
rolipram and Ro-20-l724; PDE-V are those isozymes which specifically
hydrolyze cGMP and activity of which is independent of Ca2-CaM.
PDE-VA subtype is present in somatic cells, PDE-V and PDE-V are
present in photoreceptor and interact with G-protein transducin.
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formation in inflammatory infiltrating cells [5—7, 9, 10]. The
NADPH oxidase complex is present not only in professional
phagocytosing cells, that is, leukocytes and macrophages, but
also in cells which populate glomerulus [15, 16]. In view of
these considerations, we determined which major types of PDE
isozymes are present in glomeruli, and we then tested the
hypothesis that selective inhibitors of PDE isozyme(s) can
suppress ROM formation in resident cells of glomeruli.
Methods
Male Sprague-Dawley rats (200 to 250 g body wt) had free
access to tap water and food (Purina Laboratory Rat Chow,
Ralston Purina Company, St. Louis, Missouri, USA) prior to
experiments. Glomeruli were prepared from rat cortical tissue
using a sequential sieving method as done in our previous
studies [17—19].
Briefly, rats were anesthetized by i.p. injection of pentobar-
bital sodium (90 mg/kg body wt) prior to insertion of a polyeth-
ylene catheter (PE-90) into the abdominal aorta inferior to the
renal arterial bifurcation. The vena cava was cut above the
diaphragm and the kidneys were perfused (10 mI/mm) in situ
with 60 to 80 ml of pre-warmed (37°C) Hanks' balanced salt
solution (HBSS) followed by ice-cold HBSS until both kidneys
were completely blanched. The kidneys were then quickly
removed and decapsulated and placed in ice-cold HBSS. All
subsequent preparation was conducted at 0 to 4°C. Cortical
tissue was then dissected free and finely minced before passing
through a stainless steel sieve (250 jsm pore size). The resulting
suspension was passed several times through a 22 gauge needle
to ensure complete dispersion and sequentially sieved through
Nitex nylon mesh (Tetko Inc.) of 390, 250, and 211 jsm pore
openings. The cortical suspension was then centrifuged at 800
X g for five minutes. The pellet was resuspended in HBSS and
passed over a 60 M sieve to collect the glomeruli. The
glomeruli were pelleted in a pre-weighed corex tube and the
final suspension (approximately 30 mg/mi; wet/wt) was resus-
pended in HBSS and kept on ice until experimentally used.
Yield and viability of glomeruli were similar as reported in our
preceding studies [17—19].
For fractionation to "cytosol" and "membranes" [20, 21],
glomeruli were homogenized in a medium of the following
composition (final concentrations): 0.3 M sucrose, 5 mrvi MgCI2,
1 mM EDTA, 1 mri EGTA, 5 mrs f3-mercaptoethanol, 0.1 tsM
leupeptin, 0.1 M pepstatin, and 0.1 sM phenylmethylsulfonyl
fluoride and 20 mrvi Tris [tris-(hydroxymethyl) aminomethane]
adjusted to pH 7.4, by 10 strokes in a Potter-type teflon-glass
homogenizer. Homogenate was ultracentrifuged at 100,000 X g
for 60 minutes and the supernatant was decanted and stored on
ice. The pellet was rehomogenized and ultracentrifuged again as
described above. The first and second supernatants were
pooled to constitute the total soluble fraction or "cytosol." The
washed pellet was resuspended in homogenizing buffer contain-
ing 0.1% Triton X-100 to release "latent" PDE activity [22].
This total membrane fraction is referred to as "membranes"
[20, 21].
Phosphodiesterase (PDE) assay
The activity of PDE was measured by incubating the extracts
or homogenate fractions (cytosol or membranes) in a reaction
mixture (final volume 100 tl) of the following composition (final
concentrations): 10 mt MgSO4, 2 mi EGTA, 0.1% bovine
serum albumin, 15 mrs Tris-HC1 adjusted to pH 7.4, and either
0.5 sM [3H]-cAMP or [3H]-cGMP as substrate [20, 21]. In
experiments examining the activity of Ca2-calmodulin-depen-
dent PDEs, the reaction mixture also contained 2.01 mM CaCl2,
to obtain 10 LM Ca2, and 10 g/ml of calmodulin (CaM). The
PDE activity in aliquot samples incubated without Ca2 and
CaM (but containing 2 mrvt EGTA, vide supra) was subtracted
as basal activity [20, 21]. PDE-III and PDE-IV activities were
determined as cAMP-PDE inhibitable by 3 LM cilostamide or
rolipram, respectively [22]. At these concentrations (3 tM) both
rolipram and cilostamide cause maximal inhibition of corre-
sponding PDEs [20, 22]. In preliminary experiments we deter-
mined that by increasing the dose of rolipram from 3 jsM to 10
LM has only a slightly higher inhibitory effect. Therefore, as in
our preceding studies [22] we employed 3 sM of rolipram and
cilostamide as maximum doses in the following experiments.
The PDE-II activity was determined as the difference in cAMP-
PDE without or with 5 LM cGMP [22]. In experiments exam-
ining the effect of PDE inhibitors, stock solutions of all inhibi-
tors were made in 100% dimethylsulfoxide (DMSO) and the
incubation media (including controls) contained, after final
dilution, 0.1% DMSO. Hydrolysis of cyclic-3',S'-nucleotides
was less than 20% of the substrate and was linearly proportional
to incubation time and enzyme protein concentration [20—22].
Protein content was determined by the Bradford's method [23].
Measurement of ROM by chemiluminescence
To monitor the production of ROM by glomeruli, light
emmision from glomeruli was determined by a procedure de-
scribed previously by Shah [3, 24] with minor modifications.
The light emmision from glomeruli incubated in liquid scintilla-
tion vials in a medium containing luminol was measured with a
liquid scintillation system (Model LS 6000SC, Beckman Instru-
ments) set on out-of-coincidence mode. All PDE inhibitors,
when used, were dissolved in DMSO to a final concentration of
0.1%. The reaction mixture in each vial consisted of 30 M
luminol, 0.1% DMSO alone (controls) or with added test agents
in HBSS sufficient to achieve final volume of 2 ml. Then the
background luminescence of each vial was determined. Gb-
meruli in suspension (100 p1 of 30 mg/mi wet wt) preincubated
at 37°C for 10 minutes were added to the vial, mixed, and a
second count was taken. At the same time, an aliquot of
glomeruli was removed for protein determination by a modified
method of Lowry et a! [25] as in our previous studies [21, 22].
After six minutes, phorbol myristate acetate (PMA), final
concentration 10 tg/ml, was added and chemiluminescence
measurements continued at one minute time intervals for up to
20 minutes after the addition of PMA, when the plateau was
reached. After subtraction of the basal counts, data were
expressed in cpm per milligram of protein. The time course of
the chemiluminescence response is shown on Figure 1.
For measurements of cAMP, an additional aliquot of glomer-
uli was incubated under the same conditions as used for
determination of chemiluminescence. At the end of the incuba-
tion period, the reaction was stopped by the addition of an equal
volume of ice-cold 10% TCA. The gbomeruli were homogenized
and the mixture was stored frozen at —20°C until analysis. The
TCA was extracted by water-saturated ether and cAMP content
was determined in duplicate by radioimmunoassay (RIA) on
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Fig. 1. The time course of the chemiluminescence response of glomer-
uli to 10 jsis PMA without (control -U-s-) or with 3 I.LM rolipram
(-[J-D-). Bars above the lines show periods from which PMA-stimulated
values were determined.
preacetylated samples as in our previous studies [17—2 1]. As a
rule, the effect of the tested agents was assayed when glomeruli
were exposed to stimulation by 10 pg/mi PMA. In a preliminary
experiment we affirmed that 10 pg/mi PMA elicits maximum
increase in chemiluminescence [3]. The effect of PDE inhibitors
and other tested agents was expressed as a percent change
computed as follows:
cpm in control vial — cpm in presence of test agent
cpm in control vial
In preliminary control experiments we determined the addi-
tion of superoxide dismutase (SOD) inhibited chemilumines-
cence by 62%. Further, we determined whether tested agents
may interfere with chemiluminescence elicited by ROM. The
chemiluminescence elicited by ROM generated by xanthine-
xanthine oxidase system [3] was not influenced by the addition
of rolipram, cilostamide, 8-MeoM-IBMX, zaprinast or forsko-
un.
To test whether rolipram may inhibit NADPH oxidase com-
plex directly, isolated suspended glomeruli were disrupted by
ultrasound treatment [26], centrifuged for 10 minutes at 800 X g
at 4°C and the supernatant was used for NADPH oxidase assay
[26]. The NADPH oxidase activity, 02 production, was deter-
mined in the supernatant by measuring the rate of superoxide
dismutase-inhibitable ferricytochrome c reduction [26] without
(control) or with addition of 3 M rolipram.
Since the effects of PDE isozymes' inhibitors were measured
in most experiments in glomeruli stimulated with PMA, that is
in a state of maximally activated protein kinase C (PKC) [3], in
control experiments we explored whether rolipram and cilosta-
mide might display direct inhibitory effects upon PKC. The
inhibitors were tested on PKC prepared from rat brain using a
method employed previously by Walton et al [27]. We em-
ployed, in principle, the assay for PKC described by Abraham
et al [28] with the following modifications. The mixture of
protease inhibitors was not included, the incubation was carried
out at 30°C instead of 37°C, the final reaction volume was 80 .d
and the reaction was terminated by spotting 40 d of incubation
mixture onto Whatman P 81 paper, with subsequent immersing
in 10 mts Na pyrophosphate and 1% H3P04 and three addi-
tional washes (15 mm each) in 1% H3P04. The PKC activity
was assayed by incubating 80 d mixture containing (final
concentrations): 50 M 32P-y-ATP (20 xCuIml), 400 jig/mi
histone III-S, 0.4 mM EDTA, 0.4 mrr EGTA, 10 mM MgCI2,
0.01% Triton X-lOO, 0.124 jxg/ml PKC protein and 35 ms
Tris-HC1 (pH 7.4). The PKC was assayed without (basal
activity) or the stimulated activity with (final concentrations): 1
mM CaCl2, 0.1 pM PMA and 100 g/m1 phosphatidyl-L-serine
for 20 minutes at 30°C [28].
30 Measurement of cAMP-dependent protein kinase (PKA)
activity in situ
To determine cAMP PKA activity we employed a method
described by Corbin [29] that was also used in our previous
studies [30, 31] with minor modifications. The glomeruli were
incubated either without added agents (controls), or with 3 pM
rolipram, or with 10 M forskolin, similarly as described for
chemiluminescence assay, except for the absence of luminol in
the medium. After the addition of PMA, the incubation contin-
ued for 18 minutes and was terminated by chilling the mixture to
0 to 4°C and the glomeruli were pelleted by centrifugation at
2,500 x g for five minutes at 0 to 4°C. The medium was
discarded and the packed glomeruli were homogenized in a
medium containing (final concentrations): 0.25 M sucrose, 0.5
mM IBMX, 4 mi,s EDTA, and 20 mr's MES-NaOH buffer, pH
6.8. The homogenate was centrifuged at 27,000 x g for 30
minutes at 0 to 4°C and the protein kinase activity was assayed
in the supernatant. Before protein kinase assay, the protein
concentrations in supernatants were determined by the modi-
fied method of Lowry et al as described above [25].
The cAMP-dependent protein kinase activity was measured
by the incorporation of 32P-y.ATP into the synthetic oligopep-
tide substrate Kemptide [32]. The glomerular extract was
incubated in a mixture containing (final concentrations): 20 mM
MES-NaOH, 0.4 mM EGTA, 0.1 mrs EDTA, 8 mrs NaF, 0.6
mg/mi bovine serum albumin (BSA), 160 5M "Kemptide"
(LRRASLG), pH 6.8, either with or without 1 sM added cAMP.
The reaction was started by the addition of glomerular extract
(2 pg of protein per tube); the incubation was carried out for six
minutes at 30°C and stopped by placing the incubation mixture
in 2 x 2 centimeter squares of phosphocellulose ion exchange
paper (Whatman P 81) which were then immersed immediately
into 10 mM Na4P2O7 in 1% H3P04. The papers were then
washed (3 x 15 mm) with 1% H3P04 with constant agitation.
The papers were dried and 32P radioactivity was determined by
liquid scintilation counting. Autophosphorylation of glomerular
extract was negligible. The PKA activity was assayed in one
aliquot without added cAMP, another aliquot with addition of 1
xM cAMP, (maximum stimulatory dose) and also in aliquot with
I /.LM added cAMP plus maximum inhibitory dose (10 M) of a
specific PKA oligopeptide inhibitor WIPTIDE [33], a pseu-
dosubstrate for PKA (TTYADFIASGRTGRRNAI-NH2). The
difference between activity without and with 10 jM WIPTIDE
was taken as specific PKA activity; the residual protein kinase
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activity in the presence of WIPTIDE was subtracted. In situ
activity of PKA was determined as a ratio of PKA activity
measured without added cAMP (—cAMP) to total PKA activity
measured with 1 xM cAMP (+cAMP) and expressed as (cAMPI
+cAMP) PKA activity ratio [29—311.
The results were evaluated statistically by t-test or paired
I-test, as specified in the Results.
Materials
Rolipram, 4-(3-cyclopentyloxy-4-methylphenyl)-2-pyrolidone
(ZK 62711) was a gift of Berlex Laboratories (Cedars Knolls,
New Jersey, USA). Cilostamide, N-cyclohexyl-N-methyl-
4(1 ,2-dihydro-2-oxo-6-quinohyloxy)butyramide(OPC-3639) was
a gift of Otsuka Pharmaceutical Company (Osaka, Japan). Ro
20-1724 (4-3-butoxy-4-methoxybenzyl)-2-inidazolidinone was
purchased from BIOMOL. Forskolin and bovine brain calmod-
ulin were purchased from Sigma Chemical Co. (St. Louis,
Missouri, USA). 8-Methoxymethyl,3-isobutyl-1-methyl-xan-
thine (8-MeoM-IBMX) was a gift of Dr. Jack N. Wells (Vander-
bilt University, Nashville, Tennessee, USA). 8-MeoM-IBMX is
a potent specific inhibitor of Ca2-calmodulin (CaM)-dependent
PDE-I, but does not inhibit calmodulin [34]. The QAE-Sepha-
dcx A-25 resin was from Pharmacia, LKB, Inc. (Piscataway,
New Jersey, USA); PKC was from Promega Corp. (Madison,
Wisconsin, USA). The cAMP-RIA kits were from BIO MED
TECH (BT-300); [8-3H]-cGMP, ammonium salt, 10 to 30 Ci!
mmol, [2,8-3H]-cAMP, ammonium salt, NEN (NEX 275) 30 to
50 Ci/mmol, and 32P-y-ATP were puchased from Amersham
Co. (Arlington Heights, Illinois, USA). The nylon nitex sieves
were from Tetko Inc.; Kemptide and WIPTIDE were pur-
chased from Peninsula Labs Inc. Rp-cAMPS and Sp-cAMPS
were from Research Biochemicals International (Natick, Mas-
sachusetts, USA). All other reagents and chemicals, of the
highest purity grade, were purchased from standard suppliers.
[3H]-cAMP and [3H]-cGMP were, prior to use as substrates in
PDE assays, purified according to a method of Kincaid and
Manganiello [35].
Results
PDE activities in glomeruli
The activities of cAMP-PDE and cGMP-PDE were assayed
in cytosol and total membrane fraction [20, 21] prepared from
glomerular homogenate. Overall total cAMP-PDE activity,
measured in the presence of activating agents, was higher (P <
0.002, t-test) in cytosol (1048 121 pmol cAMP/minlmg pro-
tein; N = 10) than total cGMP-PDE (553 49 pmol cGMP/
mm/mg protein; N = 11). Both cAMP-PDE and cGMP-PDE
activities in cytosol were more than three times higher than
corresponding activities in membranes (Fig. 1).
The presence of five major types (families) of PDE isozymes
was surveyed using sensitivity to specific modulators and
selective synthetic inhibitors as criteria [13, 14]. Of all PDE
isozymes which accept cAMP as a substrate, that is, cAMP-
PDEs, both cytosol and membranes from glomeruli contained
PDE-II, PDE-III and PDE-IV (Fig. 2), whereas Ca2/CaM-
dependent PDE-I hydrolyzing cAMP was not detected. PDE-II
activity was significantly higher than either PDE-IV or PDE-III
(Fig. 2) and represented about 64% of all cAMP-PDE activity in
the cytosol, as assayed under present conditions.
POE-Il PDE-IlI PDE-IV
POE-I PDE-V
Fig. 2. Activities of PDE isozymes in glomeruli hydrolyzing cAMP (A,
cAMP-PDE) and hydrolyzing cGMP (B, cGMP-PDE). Each bar de-
notes mean SEM of N = 8, from 3 independent experiments. Cytosolic(•) and membrane (0) fractions were prepared as described in Meth-
ods. Activities of cAMP-PDE and a cGMP-PDE were assayed with 0.5
fLM cAMP or 0.5 M cGMP, respectively, as substrates. Unless
specified, PDE activities were assayed in the absence of Ca2t PDE-III
is defined as cAMP-PDE supressible by 3 fLM cilostamide; PDE-IV is
cAMP-PDE activity supressible by 3 M rolipram [20—22]. PDE-I is
cGMP-PDE stimulated by 10 M Ca2 and 10 tg/ml CaM; PDE-VA is
cGMP-PDE activity assayed in the absence of Ca2 and CaM. A
(cAMP-PDE). PDE-II activity is significantly (P < 0.005, f-test) higher
than PDE-III and PDE-IV, the latter two PDEs are not significantly
different from each other. B (cGMP-PDE). PDE-I is significantly (P <
0.01, f-test) lower than PDE-V. Activities of all PDE isozymes were
significantly (by f-test) lower (4 times or more) in membranes than in
cytosol.
Lack of PDE-I activity for sufficient hydrolysis of cAMP was
unlikely due to employed assay conditions. To verify this we
assayed simultaneously in the same experiment and using the
same reagents, cytosol from glomeruli and cytosol from inner
medullary collecting duct cells grown in vitro [21]. With the use
of 0.5 M cAMP as a substrate in cytosol from glomeruli no
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Additions
Chemiluminescence cpm x 104/mg protein
Basal with 10 sg/ml PMA
Control (no additions) 120 20 1,300 229
3 /LM rolipram 100 21 807 181k% —19 6%b —38 7%bC
Ca2/CaM-dependent activity was detected, whereas consider-
able PDE-I activity was readily found in cytosol of inner
medullary collecting duct cells (basal activity of cAMP-PDE
without Ca2/CaM was 316 14 pmol cAMP/mm/mg protein
and after addition of Ca2/CaM the activity was significantly
increased (P < 0.05, t-test, N = 3) to 538 14 pmol cAMP!
mm/mg protein. PDE-II, measured with cAMP as substrate,
was stimulated by added cGMP in a dose-dependent manner;
the 1/2 max stimulatory concentration was found to be about 0.2
M cGMP.
From PDEs hydrolyzing cGMP, the predominant activity
was the Ca2-independent cGMP-PDE(PDE-VA) and much
lower was Ca2/CaM-dependent activity that is, PDE-I, which
was about 22% of total cGMP-PDE activity (Fig. 2). The
Ca2-independent PDE-VA showed relatively low sensitivity to
the inhibitory effect of 5 LM zaprinast (— 18%) while 5
dipyridamole had higher inhibitory effect (—59%).
ROM generation in glomeruli
Glomeruli showed spontaneous basal ROM generation which
increased about tenfold in response to incubation with 10 pg/ml
PMA (Table 1, Fig. 1). All subsequent measurements of ROM
generation were conducted in the presence of 10 p.g/ml PMA
(Fig. 1). In experiments examining the effect of PDE isozyme-
specific inhibitors and other agents upon ROM generation,
aliquots of the each preparation of glomeruli were incubated
simultaneously under the same conditions in the presence of 10
zg/ml PMA. One aliquot was used to measure ROM generation
by chemiluminescence (Fig. 3A) and the other to determine
cAMP accumulation (Fig. 3B). Incubation of glomeruli with
rolipram resulted in a pronounced inhibition (—
—40%) of ROM
generation (Fig. 3, Table 1); rolipram also inhibited to a lesser
degree (— —20%) the basal ROM formation, that is, without
stimulation by the added PMA (Table I). Cilostamide, a selec-
tive inhibitor of PDE-III, caused significant but much less
extensive (--- — 14%) inhibition of ROM formation than rolipram
(Fig. 3). On the other hand, neither 8-MeoM-IBMX (specific
inhibitor of PDE-I) nor zaprinast (inhibitor of PDE-V) altered
ROM formation (Fig. 3).
Notably, rolipram and cilostamide suppressed ROM without
detectable increase of cAMP content in incubated glomeruli
(Fig. 3B). Incubation of glomeruli with 10 iM forskolin inhib-
ited ROM generation to similar degree as rolipram, but in
contrast to rolipram, forskolin increased cAMP accumulation
tenfold along with the inhibition of ROM generation (Fig. 3).
— — i_I
— —
B RP B CS B FSK B MeoM- B ZAP
IBMX
Fig. 3. Effect of agents influencing cAMP and PDEs upon generation
of ROM in glomeruli (A) and accumulation of cAMP (B). RP = 3 /LM
rolipram; Cs, 3 cilostamide; FSK, 10 M forskolin, MeoM-IBMX,
3 M8-methoxymethyl-IBMX; ZAP, 3 M zaprinast. A. "ROM forma-
tion" denotes effects of tested agents upon rate of ROM generation in
the presence of 10 g/ml PMA, expressed as % change from the
control, basal value (no additions). RP, CS and FSK caused significant
((-test) inhibition, 8-MeoM-IBMX and ZAP were without effect. B.
Content of cAMP (glomeruli plus medium) accumulated in the incuba-
tion mixtures of aliquots of glomeruli in which ROM generation was
determined, see corresponding bars in upper panel. Left side bar, B,
denotes basal value without additions, right side bar denotes value with
tested agents. Only FSK increased (*P < 0.05, 1-test) the content of
cAMP significantly. Each bar (ROM generation, A) or cAMP content
(B) denotes mean SEM of 3 to 5 paired experiments.
Finally, addition of 100 sM Sp-cAMPS, an active stereoisomer
of thio-derivative of cAMP [36], also decreased ROM genera-
tion (—24 4%, mean sEM; N = 3, P <0.05, paired t-test).
In view of these findings, we investigated whether rolipram
might have inhibited the burst of ROM generation by direct
action upon NADPH oxidase or rather via cAMP signalling
pathway [9—121 due to its inhibition of PDE-IV. Very small
changes in cellular cAMP content or redistribution of cAMP
within cells can be detected by an increase of in situ activity [29,
37—39] of cAMP-dependent protein kinase (PKA). We observed
that incubation of glomeruli with 3 jsM rolipram, that is, under
Table 1. Effect of roliprarn upon chemiluminescence, basal and
stimulated by phorbol myristate acetate (PMA) in glotneruli incubated
with rolipram
Each value denotes the mean SEM of N = 6 experiments.
a Value is significantly lower (P < 0.05; paired 1-test)b The percent inhibition is significant (P < 0.05; paired 1-test)
C Valuewith PMA is significantly (P < 0.05, paired (-test) higher than
basal value
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conditions that rolipram caused inhibition of ROM formation
(Fig. 3A and Table 1) without apparent change in total cAMP
accumulation (Fig. 3), resulted in significantly (+111%) in-
creased (Fig. 4) the in situ PKA activity, as determined by
measurement of the (—cAMP/+ cAMP) PKA activity ratio
[29—31]. Incubation of glomeruli with forskolin resulted in
almost complete in situ activation of PKA, which was about
two times higher than PKA activation elicited by rolipram (Fig.
4). It is now well documented that Rp-cAMPS stereoisomer of
thio-derivative of cAMP competes with cAMP for binding on
regulatory subunits of PKA without activating the kinase [36].
In this respect, we have shown that inclusion of Rp-cAMPS to
medium in which glomeruli were incubated with rolipram
prevented the suppressory effect of rolipram upon ROM gener-
ation (Table 2). Finally, we explored whether rolipram might
have inhibited NADPH oxidase activity and/or protein kinase C
(PKC) activity by direct action. We found that 3 M rolipram
inhibited neither PKC (Table 3) nor influenced NADPH oxidase
activity determined in cell-free extract (data not shown).
Discussion
Our observations show that PDE isozymes which can hydro-
lyze cAMP in cells which populate glomeruli include PDE-II,
PDE-III and PDE-IV (Fig. 2); PDE-I was detected only with
Conditions
Inhibition of ROM
(%) generation P valuea
3 M rolipram —42 9% <0.05
3 sa rolipram —10 14% NS
+ 100 LM R — cAMPS
Conditions
Protein kinase C activity
uno1 32P/20 mm/mg protein
Basal (no activators added) 4.6 3.0
Stimulated with Ca2, PMA and PS 155.6 5.Oa
Stimulated with Ca2, PMA, PS and 3 152.0 5.2
/LM rolipram
Stimulated with Ca2, PMA, PS and 154.2 6.2
3 j.LM cilostamide
For details of experimental design see Methods. Stimulatory agents of
PKC were: 0.1 sM PMA, (phorbol myristate acetate); 1 ms Ca2
(calcium chloride) and 100 sg/ml PS (phosphatidylserine).
Data are mean SaM; N = 4.
a Significantly higher than basal value (P < 0.001, 1-test); not signif-
icantly different (P> 0.5; 1-test) from values with added 3 M rolipram
or 3 M cilostamide
use of cGMP but not cAMP as a substrate (Fig. 2). Localization
of these PDE isozymes in the major cell types present in the
(decapsulated) glomerulus, that is, podocytes, mesangial cells
and endothelial cells, remains to be determined. According to a
recent preliminary report [40], activities of PDE-IV and PDE-I
hydrolyzing cGMP, as well as minor activity of PDE-II were
observed in rat mesangial cells grown in primary culture. In our
own preliminary experiments [41] on primary cultured rat
mesangial cells we found PDE-IV, and to a lesser degree
PDE-III, but no PDE-I hydrolyzing cAMP was detected. Al-
though all nephron segments were not yet examined for PDE
isozyme composition, the diversity is obvious by comparing
glomeruli with inner medullary collecting ducts (IMCD). Unlike
in glomeruli, IMCD lack PDE-II, and PDE-IV is a predominant
isozyme hydrolyzing cAMP [42].
In view of our findings on PDE isozymes in glomeruli (Fig. 2)
and cognizant that specific PDE isozymes can modulate ROM
burst in inflammatory cells [5—10], we investigated the effects of
selective PDE inhibitors upon ROM generation and upon cAMP
signaling pathway in glomeruli. A chemiluminescence method
has been employed primarily for its sensitivity in this study. It
is realized that future analysis of the ROM system and dynam-
ics of individual ROM species need to be determined by more
specific methods.
Forskolin, a potent general activator of adenylate cyclase [43]
which caused a huge (lOx) increase in accumulation of cAMP
(Fig. 3), decreased ROM formation in glomeruli, similarly as
previously reported by Myanoshita, Takahashi and Endou [44].
In contrast, incubation of glomeruli with the PDE-IV inhibitor
• 1.0
Table 2. Effect of cAMP antagonist Rn-cAMPS upon inhibition of
ROM generation by rolipram
P<0.05
• 0.8
The experimental design was the same as described for experiments
portrayed on Fig. 3, see Results.
Data are mean SEM of N = 3 experiments. NS denotes not
significant (P> 0.5).
apvalue (paired 1-test) for significance of inhibition
Table 3. Lack of interaction of rolipram and cilostamide with protein
kinase C
• 0.2
Basal RP
(3pM)
FSK
(10 pM)
Fig. 4. Effect of 3 pi rolipram (RP) and JO pM forskolin (FSK) upon
in situ activity of cAMP-dependent protein kinase in glomeruli. Each
bar denotes means SEM of 3 to 4 experiments. Ordinate: (—cAMP!
+cAMP) protein kinase activity ratio.
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rolipram (3 M) caused no detectable increase in cAMP content
but suppressed ROM formation to the same extent as forskolin
(Fig. 3). Rolipram inhibited not only PMA-stimulated, but also
basal, spontaneous ROM generation (Table 1). Another struc-
turally distinct and selective PDE-IV inhibitor, Ro-20-l714 [13,
141, also suppressed ROM generation (data not shown). Cilos-
tamide, a specific inhibitor of PDE-III, in the same concentra-
tion as rolipram (3 sM) also blunted ROM generation without
change in cAMP content, albeit to a much lesser degree (Fig. 3)
despite that PDE-III activity was as high as PDE-IV (Fig. 2).
Considering the pattern of responses to rolipram and to
forskolin in terms of ROM generation and cAMP accumulation
by glomeruli (Fig. 3), the mechanism by which rolipram inhibits
ROM formation without noticeable increase of cAMP content
called for clarification. Since rolipram did not act on ROM as
scavenger (Methods), we explored whether rolipram might have
acted via a cAMP-signaling pathway despite measurable in-
crease in cAMP. Our finding that incubating glomeruli with 3
xM rolipram resulted in a clear-cut in situ activation of PKA
(Fig. 4) strongly suggests that rolipram, by virtue of inhibiting
PDE-IV, caused a discrete increase or redistribution of cAMP,
perhaps only in some cell types and/or in some specific cellular
compartment in glomeruli. Very small, analytically undetected
increases or redistribution of cellular cAMP [29, 37, 38, 451can
cause increased cAMP binding onto the regulatory subunit of
PKA [29, 37—39, 45—47], induce the dissociation of PKA het-
erotetramer into regulatory (R2) and catalytic (C2) subunits, and
increase the rate of protein substrate phosphorylation by the
catalytic subunit. Our interpretation suggesting that rolipram
inhibited ROM generation via in situ PKA activation is sup-
ported by the finding that Rp-cAMPS, a specific inhibitor of
PKA activation by cAMP [48], antagonized the inhibition of
ROM generation caused by rolipram (Table 2), whereas its
active stereoisomer Sp-cAMPS [36], when added to glomeruli
significantly suppressed the ROM burst (Results). The notion
that rolipram indeed supressed ROM burst via activation of
cAMP-PKA signaling pathway is further supported by our
observations that rolipram inhibited neither the activity of
protein kinase C (Table 3) nor influenced NADPH oxidase
when added directly into cell-free systems (Results).
It should be stressed that forskolin, which induced a several-
fold (lOx) increase in accumulation of cAMP (Fig. 3) and
virtually complete in situ activation of PKA (Fig. 4), did not
inhibit ROM burst to a higher degree than rolipram (Fig. 3).
Such a comparison strongly suggests that rolipram activated the
cAMP-signaling pathway either only in a specific population of
glomerular cell types(s) andlor in a discrete cellular compart-
ment. It follows that such a quantitatively limited effect upon
glomerular cAMP by rolipram was sufficient to suppress the
burst of ROM generation in the glomeruli to a maximal extent
achievable under present experimental conditions (Fig. 3). We
thus propose that ROM formation in glomeruli is modulated by
a distinct cAMP-signaling pathway, a specific catabolic branch
of which is rolipram-sensitive PDE isozyme type-TV. It remains
to be determined whether inhibition of PDE-III by cilostamide
accompanied by quantitatively minor ROM-suppressory effect,
operates in the same sites of ROM generation and by similar
mechanism as does rolipram. Lack of the effects of MeoM-
IBMX or zaprinast (Fig. 3) underscores the specificity of the
modulatory role of PDE-IV and also indicates that the inhibi-
tory effect upon ROM generation is specific for cAMP com-
pared to cGMP [13]. Thus, comparison of effects of forskolin
and rolipram as well as other tested agents argues in favor of
our proposition that the activation of the PDE-IV-controlled
cAMP signaling mechanism alone elicites maximum suppres-
sive effect upon ROM burst in glomeruli.
Interpretations of our present findings are limited by several
features. The present experiments were conducted on whole
glomeruli which consist of several types of cells: visceral
epithelial, endothelial, and mesangial cells [49]. In the future
studies it should be determined which sites are specific for ROS
generation, that is, cell types and/or cell compartments, and
whether these sites coincide with the cAMP-signaling system
controlled by PDE-IV. Such studies will require extensive
methodologic preparation. Another remaining problem chal-
lenging the interpretation of these studies is to determine the
exact location of the abundant glomerulus PDE-II (Fig. 2), and
also whether this PDE isozyme plays a regulatory role in cAMP
metabolism pooi that modulates ROM generation. It can be
perhaps expected that PDE-II is localized in glomerular endo-
thelial cells, in analogy with studies of PDEs in endothelial cells
from other tissues [50]. Investigations into the role of PDE-II
are, to a certain degree, more difficult than for other PDE
isozymes, since no truly specific inhibitor of PDE-II is presently
known [13, 14]. Finally, it remains to be discerned which ROM
species are most relevant for the ROM burst response as well as
for the pathogenic impact.
The mechanism by which rolipram-induced in situ activation
of PKA suppresses ROM formation in glomerular cells should
be briefly considered. It seems likely that most of ROMs in
glomeruli, especially in response to inflammatory stimuli, are
generated by the NADPH oxidase complex [15, 16, 51]; the
activity of xanthine-xanthine oxidase system is rather low in
glomeruli [52]. According to current knowledge the NADPH
oxidase complex generates ROM only when assembled from
three cytoplasmic and three membrane subunit components
[51, 53].
Although the NADPH oxidase complex system is presently
best described in leukocytes, it apparently exists in analogous
variants in other cell types such as fibroblasts [54], in glomer-
ular visceral epithelial cells [15], mesangial cells [15, 16], and
glomerular endothelial cells [15, 16]. It is now known that the
assembly of cytoplasmic components, the protein kinase
C-phosphorylated p47°" and p671h0( with membrane-bound
flavocytochrome b558 into active NADPH oxidase complex
requires the presence and co-assembly of two low molecular
weight GTP-binding proteins (LMWG) of the Ras superfamily
[55, 56]: Rac-1 in cytoplasm and membrane-bound Rapla [51].
Recent studies indicate that cAMP-dependent phosphorylation
of Rapla catalyzed by PKA [57] blocks assembly of NADPH
oxidase components into active complex [11] and consequently
prevents ROM generation [58]. It would not be surprising if
rolipram-induced cAMP-dependent activation of PKA (Fig. 4)
suppresses the ROM generation in glomeruli by a similar
mechanism [11, 57, 58], that is, by cAMP-dependent phosphor-
ylation of Rap la, the LMWG component of NADPH oxidase
complex in membranes of glomerular cells. However, at the
present time this proposition remains only a working hypothesis
posited by the authors.
In conclusion, this study provides evidence that selective
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PDE-IV inhibitor(s) can, in micromolar concentrations, cause a
marked suppression of ROM generation in glomerular cells.
Our findings are consistent with the proposed working hypoth-
esis that activation of a specific cAMP-signaling pathway which
includes PDE-IV, can inhibit ROM formation via cAMP-depen-
dent phosphorylation of a LMWG protein such as Rapla [11,
57, 58], which in phosphorylated state blocks assembly of
NADPH oxidase into active complex. Hence, selective PDE-IV
isozyme inhibitors, relatively nontoxic and effective com-
pounds such as rolipram [59], might possibly emerge as novel
agents suited to attenuate, via a cAMP-mediated mechanism,
the glomerular cell injury caused by ROM in vivo.
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